Page 454 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )
P. 454

438            PART 6  ■  Neoplastic Disorders












































                                 FIGURE 22.18  V  rious   ppe  r  nces o  pl  s     cells in

                                 s  e  r o  nor    l bone     rrow. A pro  inent p  le p  r  nu-
                                 cle  r zone   n   cytopl  s  ic v  cuoles   re seen in  A    n

                                  B . T e cytopl  s   in  C  h  s    reticul  r   ppe  r  nce. T e

                                 other cells in  A    re    nonph  gocytic reticul  r cell   n

                                   l  te polychro    tic erythrobl st. (Reprinte    ro   Mills

                                 SE. Histology  or Pathologists, 3r   e  , Phil    elphi  , PA:
                                 Lippincott Willi    s & Wilkins, 2007, with per  ission.)
























                                                                                                                               ount o   ree light ch  ins th  t were secrete     s   ono  er


                                                                                                                           (k  pp  ) or   i  er (l    b    ).
                                                                                                                                Nephelo  etric/turbi  i  etric qu  ntif c  tion o   ree k  pp


                                                                                                                             n   light ch  in h  s reve  le   th  t up to 20% o  MM c  ses
                                                                                                                           h  ve  ree light ch  in-only   ise  se in which light ch  ins in the


                                                                                                                           seru     n  /or urine   re the only i    unoche  ic  l   bnor-

                                                                                            Monoclonal                        lity  oun  .



                                                                                                                           Treatment



                                                                                                                           T e role o  ther  py in both SC  -eligible or SC  -ineligible

                                                                                              Polyclonal                     yelo      p  tients  is  to    chieve      r  pi  ,      xi  u      rug

                                                                                                                           response with   ini    l toxicity.

                                                                                                                                Multiple    yelo      is  incur  ble  with  convention  l


                                                                                                        Normal             che  other  py.
                                                                                                                                Melph  l  n-b  se    high-  ose  che  other  py  with  he    -

                                                                                                                           topoietic  ste    cell  support  incre  ses  the  r  te  o   co  plete
                               ALB   α    1     α  2         β                   γ                                         re  ission   n   exten  s event- ree   n   over  ll surviv  l. M  ny


               FIGURE 22.19  Abnor    l seru   protein electrophoretic p  tterns                                           p  tients still experience rel  pse,   n   options  or s  lv  ge ther-

               contr  ste   with    nor    l p  ttern. Polyclon  l hyperg        globu-                                     py   re li  ite  .
               line  i  , ch  r  cteristic o  benign re  ctive processes, shows    bro    -                                     P  tients  with    yelo      who  experience  rel  pse      er

               b  se    incre  se  in  i    unoglobulins,  owing  to  i    unoglobulin                                     high-  ose  che  other  py  h  ve   ew  ther  peutic  options.

               secretion by      yri     o  re  ctive pl  s     cells. Monoclon  l g      op  -                            T   li  o  i  e, len  li  o  i  e,   n   bortezo  ib   re novel   gents

               thy o  unknown signif c  nce (MGUS) or pl  s     cell neopl  si   shows

               n  rrow pe  k, or spike, owing to the ho  ogeneity o  the i    unoglob-                                     th  t  f rst    e  onstr  te    e  c  cy  in  tre  ting  rel  pse      n
               ulin   olecules secrete   by    single clone o    berr  nt pl  s     cells. ALB,                            re r  ctory MM. Angiogenesis is i  port  nt in tu  or progres-

                lbu  in. (Reprinte    ro   Rubin R, Str  yer DS. Rubin’s Pathology:                                        sion. As   n i    uno  o  ul  tory   rug, th  li  o  i  e inhibits

               Clinicopathologic Foundations o  Medicine, 5th e  , Phil    elphi  , PA:                                      ngiogenesis    n    in  uces    poptosis  o   cells  in  est  blishe
               Lippincott Willi    s & Wilkins, 2008, with per  ission.)                                                   neov  scul  ture.
   449   450   451   452   453   454   455   456   457   458   459